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Levamisole-induced vasculitis is a relatively new entity in people who use cocaine. We describe a 44-year-old
woman with a history of cocaine use who presented with a complaint of a painful rash of 2-3 month’s duration on
her extremities, cheeks, nose, and earlobes. She had not experienced fever, weight loss, alopecia, dry eyes, oral
ulcers, photosensitivity, or arthralgia. Examination revealed tender purpuric eruptions with central necrosis on her
nose, cheeks, earlobes, and extremities. Laboratory investigations revealed neutropenia, an elevated erythrocyte
sedimentation rate (ESR), presence of lupus anticoagulant, low complement component 3 (C3), and presence of
perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA). A urine toxicology screen was positive for cocaine, and
gas chromatography–mass spectrometry was positive for levamisole. Skin biopsy showed leukocytoclastic vasculitis
and small vessel thrombosis. Necrotic lesions of the nose led to its self-amputation. Large bullae on the lower
extremities ruptured, leading to wound infection and extensive necrosis that required multiple surgical
debridements. When necrosis progressed despite debridement, bilateral above-knee amputation of the legs was
performed. Once new lesions stopped appearing, the patient was discharged home. Two months later, she had a
recurrence related to cocaine use. To the best of our knowledge, this is only the second reported case of
levamisole-induced vasculitis that required above-knee amputation.
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According to July 2009 estimates, 69% of the cocaine
seized by the US Drug Enforcement Administration
(DEA) is adulterated with levamisole [1,2]. Levamisole is
a veterinary antihelminthic agent that has recently been
linked to vasculitis and neutropenia in people with co-
caine use [3,4]. We describe a cocaine user with
levamisole-induced necrosis of the skin, soft tissue, and
cartilage resulting in nasal amputation, earlobe necrosis,
and bilateral above-knee amputation (AKA). To the best
of our knowledge, this is only the second case of
levamisole-induced vasculitis requiring above-knee am-
putation to be reported in the English language* Correspondence: narora@med.wayne.edu
Department of Internal Medicine, Wayne State University School of Medicine,
Detroit Medical Center, 4201 Saint Antoine Street, Detroit 48201MI, USA
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reproduction in any medium, provided the orliterature, and it is also one of the first reported cases
with laboratory confirmation of levamisole exposure.Case presentation
A 44-year-old African American woman with history of
hypertension and asthma presented to the hospital with
a complaint of a painful rash on her extremities of 2-
3 months’ duration. The rash first appeared on her
upper extremities and then progressed to her legs,
cheeks, nose, and earlobes. She denied a history of fever,
weight loss, alopecia, dry mouth, oral ulcers, painful red
eyes, photosensitivity, myalgia, arthralgia, joint swelling,
dysphagia, miscarriages, or blood clots. The patient had
a chronic history of crack cocaine use and a smoking
history of five pack-years. On examination, her vital
signs were stable. Skin examination revealed erythema-
tous maculopapular purpuric lesions on her nose,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Purpuric lesions and necrosis of both earlobes.
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(Figures 1 and 2). She had several large violaceous pla-
ques and flaccid bullae on her upper and lower extrem-
ities and a stage-II ulcer on the medial surface of her
right ankle with some serosanginuous discharge. Other
physical examination results were normal.
Laboratory investigations revealed leukopenia with a
white blood cell count (WBC) of 2,600 cells/μL, neu-
tropenia with an absolute neutrophil count (ANC) of
900 cells/μL, an elevated erythrocyte sedimentation
rate (ESR) of 47 mm/hour, presence of lupus anticoagu-
lant, low complement component 3 (C3) (85 mg/dL), a
normal coagulation profile, absence of antinuclear anti-
body (ANA), absence of cardiolipin antibody, presence
of perinuclear anti-neutrophil cytoplasmic antibody
(p-ANCA) against myeloperoxidase (MPO), and ab-
sence of antiproteinase 3 (anti-PR3) antibody.
Her urine toxicology screen was positive for cocaine,
and gas chromatography–mass spectrometry (GCMS)
was positive for levamisole. Punch biopsy of the skin
from involved areas showed leukocytoclastic vasculitis
with angiocentric infiltrates of mixed inflammatory cells
and small vessel thrombosis with multiple fibrin thrombi
in the lumen of the vessels (Figures 3 and 4).Figure 2 Purpuric patches on extremities.Lesions on the lower extremities continued to expand,
and those on nose, left cheek, and ears became necrotic.
Large lower extremity bullae ruptured, leading to wound
infection and septicemia with Staphylococcus aureus,
Enterobacter cloacae, and Morganella morganii, which
were treated with broad-spectrum antibiotics. At this
point, skin involvement was estimated to be 35% of the
total body surface area, and the patient was managed in
a burn unit. Extensive and infected necrosis of the lower
extremities required fascial excision of the dead skin and
subcutaneous tissue. The patient underwent two further
surgical debridements. Despite this, necrosis progressed,
and attempts at nonoperative management were not
successful. Eventually, bilateral AKA of the legs above
the areas of necrotic skin was performed to control the
spread of nonhealing necrotic wounds. The decision to
proceed with bilateral AKA was based on the presence
of a significant degree of necrosis of leg muscles and the
poor functional prognosis for the lower extremities, even
if the nonhealing wounds eventually closed with localFigure 3 Hematoxylin & eosin staining of skin biopsy sample
showing leuckocytoclastic vasculitis with angiocentric infiltrates
of mixed inflammatory cells (white arrow) and small vessel
thrombosis.
Figure 4 Leukocytoclastic vasculitis. A dermal small vessel
showing a neutrophilic-rich infiltrate with karyorrhexis and
extravasated erythrocytes within the vessel wall and adjacent tissue.
Intra-luminal fibrin thrombi are also present.
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led to its self-amputation (Figure 5). The patient’s pain
was controlled with morphine (patient controlled anal-
gesia). New lesions stopped appearing a few days follow-
ing surgery, and she was discharged home with a
prescription of gabapentin for neuropathic pain.
Two months later, the patient was readmitted with
new painful necrotic lesions on the amputated stumps
(Figure 6). She admitted to cocaine use three days prior
to this admission. She was treated with intravenous
methylprednisolone for three days followed by tapering
doses of oral prednisone for seven days. Her pain and
lesions improved significantly, and she was discharged
home with a plan to follow up with the hospital’s plastic
surgery service for nose reconstruction.Figure 5 Necrotic lesions on the nose that eventually led to
nasal septal destruction and self-amputation.Discussion
Levamisole is a veterinary antihelminthic agent currently
used to treat worm infestations in cattle, sheep, and pigs
[5]. In the past, it was used in humans to treat various
autoimmune disorders and cancers because of its immu-
nomodulatory properties [5]. Levamisole-induced vascu-
litis (LIV) was first reported in a rheumatoid arthritis
patient in 1978 [6]. Since 2009, levamisole has also been
linked to cutaneous vasculitis in people who use
cocaine.
To the best of our best knowledge, 32 cases of LIV in
patients with cocaine use have been reported to date
[3,4,7-22]. Clinical features, laboratory results, skin biopsy
findings, and the treatment of these patients are summar-
ized in Tables 1, 2 and 3. Of the 32 patients described,
only eight had levamisole exposure confirmed by urinaly-
sis or GCMS, although other authors speculated on this
link based on the presence of levamisole in approximately
69% of the cocaine entering the United States. Among all
the reported cases, only one (published twice by different
authors, i.e., Ching et al. [15] and Mouzakis et al. [16])
had extensive necrosis requiring AKA. The patient was a
54-year-old man positive for p-ANCA who developed
fever, agranulocytosis, and extensive skin necrosis follow-
ing heavy intranasal cocaine use. Necrosis was present on
more than 50% of his total body surface area, requiring
thorough wound debridement, skin grafting, and left-sided
AKA. Unlike our patient, AKA in this case was unilateral,
and levamisole exposure was not confirmed by GCMS
since the patient presented late after the likely exposure.
The authors speculated that levamisole exposure was
probable based on the patient’s clinical presentation and
history of cocaine use. Our patient represents the most ex-
tensive confirmed case of LIV with involvement of 35% of
her total body surface area.
Levamisole was an FDA-approved drug but was with-
drawn for use in humans in the USA in 1999 due to
reports of serious adverse effects such as agranulocyto-
sis, thrombocytopenia, arthritis, and LIV [23-26]. How-
ever, it is still available for animal use in the United
States, Canada, and South America [26]. In the presence
of alternative and more efficacious veterinary antihel-
minthics, such as ivermectin [27,28], the reasons for
continued availability of levamisole for animal use are
poorly understood, especially in light of the emerging
data on the potential dangers of its addition to cocaine.
The practice of adulterating cocaine with levamisole
has increased significantly in recent years [26,29].
Several theories exist to explain the reasons for adul-
terating cocaine with levamisole. One explanation
may be levamisole’s ability to potentiate the psycho-
tropic effects of cocaine [26]. Stimulant effects of co-
caine are mediated by the blockage of presynaptic
reuptake pumps for the monoamine neurotransmitters
Figure 6 Recurrent purpuric and necrotic lesions on the amputation stumps with repeat use of cocaine.
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and peripheral nervous systems leading to their
enhanced activity [30,31]. Animal data suggest that lev-
amisole may have an inhibitory action on monoamine
oxidase and catechol-O-methyltransferase, the enzymes
that metabolize catecholamine neurotransmitters [26].
Therefore, levamisole may potentially inhibit the deg-
radation of these stimulatory neurotransmitters, pro-
longing the duration of their action and adding to the
reuptake-inhibition effect of cocaine. Clinically, this
may result in enhanced psychotropic effects [26]. Anti-
helminthic properties of levamisole are due to its
species-specific agonistic action at nicotinic acetylcho-
line receptors of the muscle cells of nematodes [32].
Cocaine may also act on the nicotinic acetylcholine
receptors of humans, resulting in increased dopamin-
ergic reuptake inhibition and glutamatergic activity
[33]. Although unlikely due to species-specific action
of levamisole, it is theoretically possible that cocaine
and levamisole may have a synergistic action at nicoti-
nic acetylcholine receptors resulting in increased nico-
tinic and dopaminergic effects [26]. Also, studies in
horses have suggested that levamisole may get metabo-
lized to aminorex, an amphetamine derivative with
stimulant effects similar to cocaine and amphetamine
[34]. Other possible explanation for using levamisole
as a cocaine adulterant may be its use as a “marker”
or “signature” compound by manufacturers to trace its
market distribution [26]. Some media reports suggest
that levamisole is used as a cutting agent for cocaine
because it adds bulk and weight to powdered crack co-
caine while retaining the appearance and look of pure
cocaine, and it also has the ability to pass cocaine pur-
ity tests used by drug dealers. Levamisole-inducedcutaneous vasculitis has been reported both with
smoked crack cocaine [17] and inhaled powdered co-
caine [21], indicating that both are adulterated with
levamisole.
In addition to levamisole, other commonly used co-
caine adulterants include local anesthetics, sugars, stimu-
lants (such as caffeine, ephedrine, phenylpropanolamine,
and amphetamines); toxins (such as quinine and strych-
nine); and inert compounds [35]. Among these cocaine
adulterants, only stimulants have been associated with
vasculitis upon chronic use. Unlike LIV, the vasculitis
associated with chronic stimulant use is usually cerebral
or systemic in distribution [35].
As LIV is usually associated with the generation of
autoantibodies such as p-ANCA, ANA, and lupus anti-
coagulant, it may be difficult to differentiate it from
autoimmune disorders such as Wegener’s granulomato-
sis and other small-vessel vasculitides. The exact patho-
genic mechanisms responsible for the formation of these
autoantibodies remain elusive. Recent reports have sug-
gested that, due to its ability to act as a hapten, levami-
sole may cause increased formation of antibodies to
various antigens and therefore lead to an immune re-
sponse involving the opsonization and eventual destruc-
tion of the leukocytes [33].
Before the recognition of levamisole as an adulterant
in the cocaine supply, cocaine alone was associated with
an p-ANCA-positive pseudovasculitis in some previous
reports [36]. Although clinical presentation and labora-
tory findings of pseudovasculitis may be similar to true
vasculitis, biopsy specimens in pseudovasculitis patients
do not reveal the typical histopathologic findings seen in
patients with true vasculitis [36]. Moreover, there is a
possibility that these cocaine-related pseudovasculitis
Table 1 Clinical features of all reported cases of levamisole-induced cutaneous vasculitis in patients with cocaine use
Authors Age/Sex Clinical findings
Gross RL et al. [3] 50 years/M Retiform pupuric plaques with ulceration on earlobes/helix and lower extremities
42 years/M Reticulate pink/purple erythematous eruptions on legs, chest, arms, and back
42 years/F Violaceous papules, reticular-purpuric plaques on arms, breasts, legs, and ears
59 years/F Purpuric, necrotic plaques and bullae on face, ears, arms, right cheek, chest, and axilla
Ullrich K et al. [4] 45 years/M Painful necrotic purpura and skin nodules on extremities and ears
49 years/F Painful purpura on extremities, trunk, and earlobes
27 years/F Painful purpura on lower extremities, arthralgia
29 years/F Purpuric lesion with central necrosis on left foot, purpuric lesions on both ears
55 years/F Episodic rash on face, trunk, and extremities
Bradford M et al. [7] 57 years/F Purpuric plaques with central necrosis on cheeks and earlobes
22 years/F Erythematous plaques with central necrosis on face, ears, legs, thighs, and buttocks
Buchanan JA et al. [8] Not specified/M Purple discoloration on left upper arm and right second toe, bilateral necrosis of ears
Walsh NMG et al. [9] 39 years/F Retiform purpura, hemorrhagic bullae on legs, trunks, and buttocks
49 years/F Retiform purpura on chest, limbs, bilateral nasal mucosal ulcers
Waller JM et al. [10] 38 years/F Retiform purpura with central necrosis on earlobes, cheeks, breast, extremities
43 years/F Retiform purpura with central necrosis on legs, arms, and pinna; l
ivedo racemosa, splinter hemorrhages
Farhat EK et al. [11] 43 years/F Retiform purpura with central necrosis on bilateral lower extremities
41 years/F Painful retiform purpuric patches on thighs, buttocks, trunk, upper extremities, and nasal tip
Click J [12] 29 years/F Calf ulcerations, retiform purpura
Geller L et al. [13] 50 years/F Stellate purpura with central necrosis on upper extremities, ears, back, and breasts
Han C et al. [14] 52 years/F Painful retiform purpura with ulceration on arms, legs, nasal tip, cheeks, ears
Ching J et al. [15]/
Mouzakis J et al. [16]
54 years/F Purpuric patches and plaques on legs, upper extremities, perinasal area,
anterior trunk, face, and ears
Jacob RS et al. [17] 41 years/F Tender purpuric patches and plaques on ears, legs, upper extremities, back, toes, and soles
48 years/F Tender purpuric patches and plaques on ears and left cheek
Lung D et al. [18] 44 years/F Stellate, purpuric macules and plaques with central necrosis on legs, abdomen, and face
Zwang NA et al. [19] 52 years/M Violaceous retiform papules/plaques on arms, legs, back, trunk, scalp, buttocks,
fingers, foot, and ear
Chung C et al. [20] 46 years/F Purpura and necrosis on bilateral ears, cheeks, and upper and lower extremities
46 years/F Bilateral ear necrosis, diffuse retiform purpura with necrosis on neck, trunk, and extremities
37 years/M Tender bilateral ear purpura and necrosis, diffuse retiform purpura on trunk and extremities
50 years/M Tender purpura and necrosis on both ears, purpura and bullae on trunk and extremities
Jenkins J et al. [21] 47 years/M Painful retiform purpura with necrotic center on legs, ears, cheek, tongue, trunk, and genitalia
John S et al. [22] 52 years/F Painful violaceous plaques and flaccid bullae on right ankle, legs, left arm, and left breast
Arora et al. [current report] 44 years/F Erythematous purpuric lesions with central necrosis on nose, cheeks, earlobes, and extremities
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ation with levamisole.
Adulteration of the majority of the cocaine supply
entering United States with levamisole is concerning, es-
pecially in view of the high frequency of cocaine use in
this country. According to the August 2005 National
Survey on Drug Use and Health (NSDUH) Report, more
than 5.9 million (2.5%) persons aged 12 years or older
used cocaine in 2002-2003 [37].Based on published reports, Levamisole-induced cuta-
neous vasculitis in cocaine users is more commonly seen
in women [3]. Clinical features commonly include a ten-
der purpuric rash in a retiform/reticular distribution
with or without necrosis [3]. In addition to leukopenia
and neutropenia, laboratory results are usually positive
for different types of auto-antibodies such as c-ANCA,
p-ANCA, ANA, and lupus anticoagulant [3]. Recurrence
or exacerbation of skin lesions with cocaine use have
Table 2 Laboratory findings of all reported cases of levamisole-induced cutaneous vasculitis in patients with cocaine
use
Authors Age/Sex Leucopenia and/or
Neutropenia
Antibodies present
Gross RL et al. [3] 50 years/M Yes, WBC -3,300/μL, ANC -2400/μL p-ANCA, ANA, LAC, c-ANCA, anti-ds-DNA
42 years/M Yes, WBC -3,200/μL, ANC - 800/μL p-ANCA, ANA, LAC, c-ANCA, IgM ACL
42 years/F No p-ANCA, c-ANCA, ANA
59 years/F No p-ANCA, ANA, anti-RNP
Ullrich K et al. [4] 45 years/M Yes, WBC -1,900/μL, ANC -1,000/μL p-ANCA, c-ANCA, ANA, IgM ACL
49 years/F Yes, WBC -3,500/μL, ANC – 0 (zero) ANA, c-ANCA
27 years/F Yes, WBC -1,800/μL, ANC -400/μL p-ANCA, c-ANCA, IgM ACL, ANA
29 years/F No p-ANCA, c-ANCA, IgM ACL, ANA
55 years/F Yes, WBC -3,700/μL, ANC -2,300/μL p-ANCA, c-ANCA, IgM ACL
Bradford M et al. [7] 57 years/F Yes, ANC -500/μL p-ANCA, IgM ACL
22 years/F Yes, ANC< 1,000/μL p-ANCA, IgM ACL
Buchanan JA et al. [8] Not specified/M Yes, WBC -1,900/μL Not reported
Walsh NMG et al. [9] 39 years/F No p-ANCA, c-ANCA, ANA, LAC, anti-HNE
49 years/F Yes, WBC -2,000/μL, ANC -400/μL p-ANCA, c-ANCA, ANA, anti-HNE
Waller JM et al. [10] 38 years/F Yes, ANC -550/μL p-ANCA, c-ANCA, LAC
43 years/F Yes, ANC -560/μL p-ANCA, IgM ACL, LAC, anti-ds-DNA,
Farhat EK et al. [11] 43 years/F No p-ANCA
41 years/F No p-ANCA, IgM ACL
Click J [12] 29 years/F No p-ANCA, c-ANCA, ANA
Geller L et al. [13] 50 years/F Yes, WBC -2,700/μL, ANC -1,400/μL p-ANCA, IgM ACL
Han C et al. [14] 52 years/F Yes, WBC -2,400/μL, ANC -1,400/μL p-ANCA, c-ANCA, IgM ACL
Ching J et al. [15]/Mouzakis J et al. [16] 54 years/F Yes, WBC -3,900/μL, ANC -300/μL p-ANCA, IgM ACL
Jacob RS et al. [17] 41 years/F Yes, WBC -1,100/μL, ANC -670/μL p-ANCA, c-ANCA, IgM ACL,
ANA, anti-ds-DNA,anti-HNE
48 years/F Yes, WBC -800/μL, ANC -300/μL p-ANCA, c-ANCA, IgM ACL, ANA,
anti-ds-DNA,anti-HNE
Lung D et al. [18] 44 years/F Yes, ANC -270/μL Not reported
Zwang NA et al. [19] 52 years/M No p-ANCA, c-ANCA, IgM ACL, ANA, LAC,
anti-HNE,anti-ds-DNA,
Chung C et al. [20] 46 years/F No p-ANCA, c-ANCA, IgM ACL
46 years/F Yes, WBC and ANC not specified p-ANCA, c-ANCA, IgM ACL
37 years/M No p-ANCA, ANA
50 years/M No p-ANCA, ANA
Jenkins J et al. [21] 47 years/M No p-ANCA
John S et al. [22] 52 years/F Yes, WBC -2,900/μL, ANC -638/μL p-ANCA +,anti ds-DNA+
Arora et al. [current report] 44 years/F Yes, WBC -2,600/μL, ANC -900/μL p-ANCA+, LAC+
Abbreviations: M=male, F= female, WBC=white blood cell count, ANC= absolute neutrophil count, p-ANCA=perinuclear anti-neutrophil cytoplasmic antibody,
c-ANCA= cytoplasmic anti-neutrophil cytoplasmic antibody, IgM ACL= immunoglobulin-M anticardiolipin antibody, ANA= antinuclear antibody, LAC= lupus
anti-coagulant, anti-HNE= anti-human neutrophil elastase antibody, anti-ds-DNA= anti-double-stranded deoxyribonucleic acid antibody,
anti-RNP= anti-ribonucleoprotein antibody.
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mixed pattern of leukocytoclastic and thrombotic vascu-
litis or an isolated thrombotic vasculopathy [3].
Cessation of cocaine use and supportive care of LIV-
related skin lesions lead to resolution of symptoms in
most of the cases. Steroids have been used in asignificant number of previously reported cases with a
variable response. The recurrent lesions in our patient
improved significantly after intravenous methylpredniso-
lone. However, due to the risk of increased susceptibility
to superimposed infections, steroid use should be lim-
ited to more severe cases that fail to respond to
Table 3 Skin biopsy findings, treatment, and response to treatment information of all reported cases of levamisole-induced cutaneous vasculitis
Authors Age/Sex Pathology Treatment Response
Gross RL et al. [3] 50 years/M Vasculitis, thrombosis, necrosis Oral prednisone,
surgical debridement
Lesions remained stable, developed auditory
hallucinations & superinfection
42 years/M Small-vessel vasculitis Supportive care Lesions improved without any intervention
42 years/F Lekocytoclastic vasculitis, thrombosis Oral prednisone Lesions improved in one week
59 years/F Small-vessel vasculitis, thrombosis Oral prednisone Lost to follow-up
Ullrich K et al. [4] 45 years/M Not reported Oral prednisone Initially improved, but symptoms recurred with
attempts to taper the steroid dose
49 years/F Thrombosis, perivascular neutrophils,
and karyorrhetic debris
Supportive, G-CSF Resolution of lesions with abstinence from cocaine
27 years/F Lekocytoclastic vasculitis, thrombosis Oral prednisone Lesions resolved with abstinence, arthralgia and
neutropenia improved rapidly with prednisone
29 years/F Not reported Supportive care, oral steroids Lesions resolved with abstinence, septal perforation &
arthralia improved with steroids
55 years/F Lekocytoclastic vascultis, thrombosis Steroids, cyclophosphamide Rapid resolution of lesions
Bradford M et al. [7] 57 years/F Intravascular thrombosis, no vasculitis Filgrastim for neutropenia Lesions resolved spontaneously, neutropenia
improved with filgrastim
22 years/F Leucocytoclastic vasculitis, thrombosis Steroids Lesions and neutropenia improved rapidly
Buchanan JA et al. [8] Not specified/M Not done Subcutaneous phentolamine
to both ears
No improvement
Walsh NMG et al. [9] 39 years/F Thrombosis, leucocytoclastic vasculitis Anticoagulation, skin
debridement and grafting
No new lesions with discontinuation of cocaine, skin
lesions healed after multiple full thickness skin grafts
49 years/F Thrombosis, no evidence of vasculitis Supportive care Lesions improved, recurrences with cocaine use
Waller JM et al. [10] 38 years/F Leukocytoclastic vasculitis, thrombosis Supportive care Lesions improved, recurrences with cocaine use
43 years/F Thrombosis of dermal vessels Supportive care Lesions improved, recurrences with cocaine use
Farhat EK et al. [11] 43 years/F Extensive thrombosis, no vasculitis Supportive care Not specified
41 years/F Thrombosis with no vasculitis Not specified Not specified
Click J [12] 29 years/F Subepidermal bullous dermatitis,
lymphocytic perivascular infiltrate
Skin grafts Lesions were healing well after 4 months
Geller L et al. [13] 50 years/F Lecocytoclastic vasculitis, thrombosis Not specified Not specified
Han C et al. [14] 52 years/F Thrombotic vasculopathy, no vasculitis Steroids (iv & oral), dalteparin,
warfarin
Lesions and neutropenia improved, had recurrences in
with repeat cocaine use, which improved with
oral prednisone
Ching J et al. [15]/
Mouzakis J et al. [16]
54 years/F Small vessel thrombosis, perivascular
mononuclear infiltrates
IV steroids, left AKA,
skin debridement, allografts
Developed extensive skin necrosis requiring
debridement and skin grafts
Jacob RS et al. [17] 41 years/F Epidermal necrosis, vascular thrombosis,
leukocytoclasis
Oral prednisone Resolution of the majority of the patient’s lesions
48 years/F Lymphocytic infiltrate, occlusive vasculopathy,
neovascularization


















Table 3 Skin biopsy findings, treatment, and response to treatment information of all reported cases of levamisole-induced cutaneous vasculitis (Continued)
Lung D et al. [18] 44 years/F Extensive thrombotic vasculopathy Not specified Not specified
Zwang NA et al. [19] 52 years/M Leukocytoclastic vasculitis Oral prednisone Lesions healed completely in 3 weeks
Chung C et al. [20] 46 years/F Small-vessel vascultits with thrombosis Steroids Initial improvement, lost to follow-up
46 years/F Multiple Intravascular thrombi IV methyl-prednisolone Gradual improvement initially, lost to follow-up
37 years/M Leucocytoclastic vasculitis Supportive Rapid improvement of skin lesions
50 years/M Leucocytoclastic vasculitis, panniculitis Supportive, antibiotics Rapid improvement of skin lesions
Jenkins J et al. [21] 47 years/M Leucocytoclastic vascultits, occlusive vasculopathy Oral & topical steroids, aspirin,
pentoxifylline
Lesions resolved over 3 months
John S et al. [22] 52 years/F Thrombotic vasculopathy, no vasculitis Supportive, surgical debridement Had new lesions with repeat cocaine use and necrotic
ulceration of old lesions requiring surgical debridement
Arora et al. [current report] 44 years/F Leucocytoclastic vasculitis, thrombosis Surgical debridement,
pain control, AKA, IV
methyl-prednisolone for recurrent lesions
Recurrent lesions improved significantly with IV
methylprednisolone
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possible adverse effects of future cocaine use. Extensive
skin involvement and necrosis may need surgical de-
bridement and skin grafting. As happened in our patient,
in extreme cases that involve extensive necrosis, ampu-
tation may be required to contain necrosis and infection.
Conclusions
Adulteration of cocaine with levamisole is widely preva-
lent in United States. Levamisole may cause cutaneous
vasculitis and neutropenia in people with cocaine use.
History of cocaine use should be explored in patients
presenting with a rash and neutropenia, and testing for
levamisole exposure should be performed in selected
patients. In cases with extensive involvement, this condi-
tion may lead to disfigurement by causing necrosis of
skin, soft tissue, and cartilage.
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